Literature DB >> 33804114

Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer.

Zhengwei Wu1,2, Yi Fei Lee2,3, Xun Hui Yeo1,2, Ser Yue Loo2, Wai Leong Tam1,2,3,4.   

Abstract

Cancer metabolism is a hallmark of cancer. Metabolic plasticity defines the ability of cancer cells to reprogram a plethora of metabolic pathways to meet unique energetic needs during the various steps of disease progression. Cell state transitions are phenotypic adaptations which confer distinct advantages that help cancer cells overcome progression hurdles, that include tumor initiation, expansive growth, resistance to therapy, metastasis, colonization, and relapse. It is increasingly appreciated that cancer cells need to appropriately reprogram their cellular metabolism in a timely manner to support the changes associated with new phenotypic cell states. We discuss metabolic alterations that may be adopted by cancer cells in relation to the maintenance of cancer stemness, activation of the epithelial-mesenchymal transition program for facilitating metastasis, and the acquisition of drug resistance. While such metabolic plasticity is harnessed by cancer cells for survival, their dependence and addiction towards certain metabolic pathways also present therapeutic opportunities that may be exploited.

Entities:  

Keywords:  cancer stem cells; cell state transition; cellular plasticity; epithelial–mesenchymal transition; phenotype switching; therapy resistance

Year:  2021        PMID: 33804114      PMCID: PMC7999312          DOI: 10.3390/cancers13061316

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  175 in total

Review 1.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

2.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Authors:  Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

Review 3.  LIN28: A Stem Cell Factor with a Key Role in Pediatric Tumor Formation.

Authors:  Ilana Carmel-Gross; Naomi Bollag; Leah Armon; Achia Urbach
Journal:  Stem Cells Dev       Date:  2016-02-17       Impact factor: 3.272

4.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

5.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

6.  Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging.

Authors:  Luca Tirinato; Carlo Liberale; Simone Di Franco; Patrizio Candeloro; Antonina Benfante; Rosanna La Rocca; Lisette Potze; Roberto Marotta; Roberta Ruffilli; Vijayakumar P Rajamanickam; Mario Malerba; Francesco De Angelis; Andrea Falqui; Ennio Carbone; Matilde Todaro; Jan Paul Medema; Giorgio Stassi; Enzo Di Fabrizio
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

7.  Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells.

Authors:  Stephen Kershaw; Jeffrey Cummings; Karen Morris; Jonathan Tugwood; Caroline Dive
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

8.  Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy.

Authors:  Chung-Yu Huang; Li-Han Hsu; Chung-Yeh Chen; Gee-Chen Chang; Hui-Wen Chang; Yi-Mei Hung; Ko-Jiunn Liu; Shu-Huei Kao
Journal:  Cancers (Basel)       Date:  2020-01-10       Impact factor: 6.639

9.  Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.

Authors:  Roman Camarda; Alicia Y Zhou; Rebecca A Kohnz; Sanjeev Balakrishnan; Celine Mahieu; Brittany Anderton; Henok Eyob; Shingo Kajimura; Aaron Tward; Gregor Krings; Daniel K Nomura; Andrei Goga
Journal:  Nat Med       Date:  2016-03-07       Impact factor: 53.440

10.  Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch.

Authors:  Su Yeon Lee; Hyun Min Jeon; Min Kyung Ju; Eui Kyong Jeong; Cho Hee Kim; Hye Gyeong Park; Song Iy Han; Ho Sung Kang
Journal:  Oncotarget       Date:  2016-02-16
View more
  2 in total

1.  Suppression of PGC-1α Drives Metabolic Dysfunction in TGFβ2-Induced EMT of Retinal Pigment Epithelial Cells.

Authors:  Daisy Y Shu; Erik R Butcher; Magali Saint-Geniez
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

2.  Development and Validation of a Combined Glycolysis and Immune Prognostic Model for Melanoma.

Authors:  Yang Yang; Yaling Li; Ruiqun Qi; Lan Zhang
Journal:  Front Immunol       Date:  2021-10-01       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.